Cross-Sector entity
Grifols is most often covered alongside CSL Behring, which appears in 2 of these 2 stories. market-trends accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. Grifols appears in 2 tracked Cross-Sector stories from February 20, 2026.
2 verified stories tracked
Last mentioned: Feb 20, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Grifols is most often covered alongside CSL Behring, which appears in 2 of these 2 stories. market-trends accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. Grifols appears in 2 tracked Cross-Sector stories from February 20, 2026. The tracked stories average 2 original sources each.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Grifols. Shared-story counts are live from our verified record — not editorial picks.
Market Peak
Projected valuation of $25.15 billion reached through global capacity expansion.
Current Milestone
Market valuation hits significant mid-term growth targets as supply meets latent demand.
Infrastructure Investment
Major fractionators announce multi-billion dollar investments in automated collection centers.
Supply Recovery
Plasma collection volumes begin to stabilize following pandemic-era disruptions.
The global immunoglobulin market is projected to reach $25.15 billion by 2031, fueled by massive investments in plasma collection infrastructure and rising demand for primary immunodeficiency treatments. This growth reflects a stabilization of the supply chain following pandemic-era disruptions and a strategic shift toward subcutaneous delivery methods.
The global immunoglobulin market is projected to reach $25.15 billion by 2031, fueled by a significant expansion in plasma collection infrastructure. This growth reflects rising clinical demand for antibody therapies and improved supply chain efficiencies across major pharmaceutical hubs.
Source: portal.sina.com.hk · manilatimes.net
